Questions discussed in this category
What are your volumes and dose/fractionation for external beam boost in lieu of tandem and ovoid or tandem and ring implant?
If so, what do you typically prescribe?
That nodal region has previously received 55 Gy in 25 fractions.
Would you consider this stage IVA (spread to adjacent organ) or IVB (spread to distant organ)? For instance, would the presence of direct lumbar verte...
Would you still discuss the option of parametrectomy/upper vaginectomy if they would have met the criteria for SHAPE?
Do you recommend completion hysterectomy after completion of child-bearing?
Pre-op stage was IB2, but post-op: tumor 4.5 cm, negative margins, no LVSI, 6/15 mm depth of stromal invasion, negative SLN.
Would you consider standard definitive chemoRT (EBRT + HDR brachytherapy)?
Cervical cancer FIGO stage IIIC2. Bloodwork shows elevated ESR and CRP.
No LN dissection was performed as it was for a suspected CIN III. Final pathology showed +LVSI, -margins (>10mm), -parametrial extension, and 1.2mm...
The 4 cm cuff recurrence occurred 3 years after definitive treatment with hysterectomy and vaginal cuff brachytherapy to 21 Gy. The recurrence had a c...
What is your practice when you have a neutropenic cervical cancer patient undergoing chemoradiation?
If so, will you recommend it universally or only for certain patient population(s)?
If so, what dose/volume is prescribed? How do you account for motion?
This is a patient in her 70s who previously received 5040 cGy adjuvant EBRT alone to the pelvis.
Aside from limit due to extent of her hysterectomy, the patient's disease does not otherwise satisfy Peters' criteria
Consider treatment of stage IVB cervical cancer with systemic therapy and local pelvic radiation therapy as in Perkins et al., PMID 31810653.
Assuming patient is <45 years old with cervical, vulvar, vaginal, anal, or head/neck cancers, or with CIN/VIN/VaIN/AIN/oropharyngeal precancerous l...
Considering this is stage IV disease, do your recommendations for definitive or adjuvant treatment (after surgery) change?
MRI pelvis shows a 3.5 cm primary that appears infiltrative and without clear parametrial extension on MRI. Staging PET negative.
Is there any ...
If yes, would you consider a minimally invasive approach despite the LACC trial results?
If no, what additional research/information is needed to cha...
Close but negative radial margins? LVSI? What fractionation/dose do you use for your vaginal cuff boost if used?
ConCerv trial: Schmeler et al., PMID 34493587
7 cm tumor limited to the cervix with no vaginal or parametrial invasion on exam and not lymphadenopathy or metastatic disease on imaging. Cystoscopy ...
Occult IB1 cervical SqCC found on simple extrafascial hysterectomy, with 4 mm deep stromal invasion and LVSI. Subsequent pelvic and para-aortic nodal ...
Could you discuss how you decide between IMRT or SBRT boost for a patient who is not able to receive intracavitary or interstitial HDR or LDR brachyth...
When would you use 5-fluorouracil instead of, or in addition to, cisplatin during chemoradiation?
When would you use 5-fluorouracil instead of, or in addition to, cisplatin during chemoradiation? When, if ever, would you offer adjuvant hysterectomy...
Ideally, treatment should be completed in 56 days (preferably < 50 days). If there has been a significant delay to brachytherapy (>2-3 months) d...
If a patient presents with metastatic disease (by virtue of extensive PA nodal burden, mediastinal/SCV involvement, no solid organs) but received urge...
Do you include pembrolizumab with platinum-taxane + bevacizumab or reserve it as a second line option?
SIBs of 55-57.5 Gy in 25 fractions are frequently mentioned with bowel volume constraints at this dose, but assuming there is no bowel nearby (e.g., b...
Would you consider additional EBRT or vaginal cuff HDR in a patient with previous tx with EBRT (45Gy) + HDR (30Gy) for a R1 resection with a radial ma...
What are the pros and cons of using uterine artery embolization with regard to how it may affect the efficacy of radiation (+/- chemotherapy)?
Are there any criteria you use to preferentially recommend primary chemoradiation instead of primary surgery?
Assuming minimal toxicities except fatigue from long, recurrent infusions.
Do you increase EBRT or brachy dose by a certain amount based on interval?
Do you recommend upfront diversion? Are there unique planning considerations such as the inability to use bladder filling? How do you boost? What are ...
Assuming the nodal assessment is minimally invasive and the patient is otherwise healthy without postoperative complications.
Consideration for localized therapy alone vs. localized therapy + systemic chemotherapy.
Do you try to keep Hb> 10 or 12? Or somewhere in between?
Patient is 38yo, has a history of narcotic abuse, and may have an undiagnosed personality disorder.
Is the QuadShot a possible option?
Could EBRT lead to rupture of the cyst?
This patient has pulmonary nodules that are too small to characterize.
Previously received pelvic EBRT and intracavitary brachytherapy. IORT was administered to the node-positive side wall at the time of exenteration.
Initially treated with definitive chemoRT but recurred with distant mets. Completed 6 cycles carb/tax/bev with minimal toxicity. Excellent performance...
Lung is biopsy proven met cervix, SBRT is planned.
Patient did not previously receive para-aortic radiation. Considering RT vs RT + chemo vs chemo alone
Recurrence was 2cm and PET confirmed local. Excision with positive margins. Current plan for salvage whole pelvic RT and vaginal cuff brachytherapy +/...
If confirmed neuroendocrine and PD-L1 pending, how would you treat?
In patient with PD SCCA 15mm transverse; 5/20mm invasion; LVSI focally present; margins negative; 0/15 Left pelvic and 0/14 right pe...
What dose and technique do you use and how do you integrate the subsequent definitive treatment plan?
The recently released STARS phase 3 RCT found improved DFS, decreased distant recurrence, with reduced toxicities for chemotherapy (cisplatin + taxol)...
Despite the LACC trial, this year's SGO had many posters and discussions around MIS for early cervical cancer.
If you offer MIS, what are the key ele...
Margins negative, no LVSI, PET/CT negative.
How would you factor in a patient with profound thrombocytopenia?
Paraaortic nodes positive to left renal vein
Would PET-positive pelvic or paraaortic lymph nodes change this recommendation?
Currently 7 weeks pregnant, diagnosis based on CKC
ex. in a patient with pulmonary micronodules, inguinal, pelvic, PA nodes
Patient is currently 7 weeks GA with 1.5cm visible lesion. MFM recommends 13wk CKC vs LEEP with cerclage at that time.
Particularly with IMRT when delineating volumes.
Lesion measures 2cm and PET is otherwise negative.
Patient with stage IIB cervical cancer treated 8 years ago, now with large (>10cm), isolated, symptomatic recurrence involving the left SCL and med...
Would you consider SBRT or brachytherapy?
What factors affect this decision?
Small bowel is usually the dose limiting OAR while planning cervical HDR brachytherapy. Having the bladder empty during treatment planning and deliver...
This has been a common practice in the community. Is there a benefit for certain patients?
What dose/fractionation would you recommend?
Patient being treated for cervical cancer noted to have a < 1 cm posterior vaginal fornix defect with a small focus epiploclia herniating into the ...
The limited data on MDA (minimum deviation adenocarcinoma) suggests it has a worse prognosis, but it is hard to disentangle this from stage, as it is ...
Would there be a substanital increase in the risk of toxicity using such a scheme?
We frequently have patients who have to travel long distance...
Would you be more or less likely to use a cisplatin-containing regimen if a patient had previously responded to chemoradiation with concurrent cisplat...
What chemotherapy and sequencing with radiation therapy would you recommend? IS surgery a component of the treatment?
Does the phase II KN-158 provide sufficient evidence to change management?
Should this be done at the time of recurrence or after failure of 1st line therapy for recurrence?
Do you have an SUV cutoff for physiologic activity of the ovary?
Do you cover common iliac nodes (L3/L4) or keep field edge at L4/L5 to reduce bone marrow toxicity?
If so, what indications would you use other than Peters criteria?
Do you use a trimmed 10 mm expansion on HR-CTV? Do you also include the entire initial extent of disease? How much does your IR-CTV coverage affect yo...
A literature search indicates that most port site recurrences are managed fairly aggressively with chemoRT or RT doses 45-66 Gy. This is understandabl...
Sequentially or do you integrate the cuff brachy with the EBRT and if so what schedule, BIW, weekly, etc?
For example, a patient with cervical or anal SCC who has missed many treatments due to side effects, low blood counts, hospitalizations, or non-compli...
Do you add an IMRT boost with possibly vaginal brachytherapy?
What are your specific protocols for monitoring and for dosing narcotics and sedatives?
In the setting of a negative lymph node sampling, would you treat a full pelvis or mini-pelvis to compensate for lack of the appropriate surgery? Is a...
In patients who don't meet traditional criteria for adjuvant chemoradiation from Peters (GOG 109) and < 2 high risk factors from Rotman (GOG 92) fo...
What exactly do you contour and what is your dose constraint to that volume?
Does using something like a vienna applicator allow you to avoid dose escalation with more external beam? How do you recommend doing a classic pa...
Some classic references recommend the coverage of the entirety of the sacrum but the volume delineation guidelines for both seem to only cover the mos...
The most recent ABS guidelines don't discuss a dose constraint for the small bowel.
Does your strategy change if bladder invasion is present?
Do you treat PAs if pelvic nodes are positive? If common iliacs are involved? Only if there are positive PA nodes?
2013519128206492187521579204421237320650206482065121000208491806618508203721962618674667117861587118068180631782615748175521171217232171401559616048166091663428516090162061588552881508315158121511549111851117549411751113620133111055812668126601067499381220612564120022550116641145411449113541120811085111011112040911083103341061110550104658003103331026171129851100509765995798829875976498502339946695829449821392759276903186668667866386008129810380638007786478396833777477526823647068426702629963845693583454925714522552285219522752265224504248564799456746054566195940224100409040384010262624862475241321502030846817424426425288247348271325
Papers discussed in this category
International journal of radiation oncology, biology, physics, 2011-02-01
Int J Radiat Oncol Biol Phys, 2013 Jul 9
JAMA Netw Open, 2021 Apr 01
Int. J. Radiat. Oncol. Biol. Phys., 2014-05-01
Cancer Nurs, 2017-04-21
Cochrane Database Syst Rev, 2010 Sep 08
International journal of radiation oncology, biology, physics, 2019-05-01
Cochrane Database Syst Rev, 2012 May 16
Int. J. Gynecol. Cancer,
Seminars in radiation oncology, 2019-04
International journal of radiation oncology, biology, physics, 2006-08-01
Gynecologic oncology, 2005-11
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-12-15
Gynecologic oncology, 1999-05
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04
Lancet,
Gynecol. Oncol., 2005 Nov 21
J. Clin. Oncol., 2011 Mar 28
BMC Cancer, 2017 Apr 28
N. Engl. J. Med.,
American journal of obstetrics and gynecology, 2011-08
Journal of the National Cancer Institute. Monographs, 2005
Pediatric blood & cancer, 2018-09
Obstet Gynecol,
Clin Transl Radiat Oncol, 2018 Jan 11
Gynecologic oncology, 2014-01
Cancer, 2000-04-15
Lancet Oncol.,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019-01
Gynecologic oncology, 2004-04
J Obstet Gynaecol Res, 2019 Sep 09
The New England journal of medicine, 2018-11-15
International journal of radiation oncology, biology, physics, 1991-07
Cancer,
The Lancet. Oncology, 2017-03
Gynecologic oncology, 2017-04
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019-01-23
Ann Oncol,
Gynecol Oncol, 2018 May 24
Int J Gynecol Cancer,
Gynecologic oncology, 2011-07
BMC Cancer, 2018 May 04
J Gynecol Oncol,
International journal of radiation oncology, biology, physics, 2008-11-15
Int. J. Radiat. Oncol. Biol. Phys., 2012 Aug 14
Practical radiation oncology, 2017
Practical radiation oncology, 2018
Radiother Oncol, 2020 Oct 14
The New England journal of medicine, 1999-04-15
Ann Oncol, 2012 Feb 21
JAMA Oncol,
Lancet (London, England), 2017-10-07
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-10
J Clin Oncol, 2019 Nov 04
Lancet Oncol, 2021 Apr 09
Int J Gynecol Cancer, 2019 Jan 04
Gynecologic oncology, 1998-08
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-10-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985-08
Cancer, 1981-08-15
Clin Transl Radiat Oncol, 2020 Apr 16
Pract Radiat Oncol, 2019 Nov
Cancers (Basel), 2021 Mar 11
International journal of radiation oncology, biology, physics, 2017-12-01
Journal of the National Comprehensive Cancer Network : JNCCN, 2006-05
Radiology, 2018-04
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2019-04
Gynecol Oncol, 2021 Jul 03
Gynecol Oncol, 2017 Sep 24
Surgical neurology international, 2017
Eur J Gynaecol Oncol,
Obstet Gynecol,
Vaccines (Basel), 2021 Apr 21
Vaccine, 2020 Aug 04
N Engl J Med, 2021 Sep 18
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017-03
N Engl J Med, 2022 Jan 19
Radiother Oncol, 2016 Sep
JCO Glob Oncol,
Gynecol Oncol, 2022 Oct 15
Am J Surg Pathol, 2015 Nov
Eur J Surg Oncol, 2022 Mar 25
Gynecologic oncology, 2003-06
American journal of obstetrics and gynecology, 2007-11
BMC Cancer, 2021 Oct 11
Gynecol Oncol, 2019 Jan 29
Int J Gynecol Cancer, 2018 Jan
BMB Rep, 2022 Sep
J Gynecol Oncol, 2019 Sep 17
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-01
Clinical Medicine Insights. Oncology, 2022 Jun 24
N Engl J Med, 2023 Mar 27
N Engl J Med, 2023 Mar 27
Int J Gynecol Cancer, 2021 Sep 07
Gynecologic oncology, 2004-03
J Clin Oncol, 2023 Jan 30
Gynecol Oncol, 2021 Sep
Rheumatology (Sunnyvale, Calif.), 2015 May 07
Annals of the rheumatic diseases, 2013 Jul 10
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2022 Mar
International journal of radiation oncology, biology, physics, 2023 Jan 12
The Lancet. Oncology, 2023 Dec
The Lancet. Oncology, 2021 Apr
International journal of radiation oncology, biology, physics, 2024 Oct 23
Int J Radiat Oncol Biol Phys, 2020 Mar 1
Radiation oncology (London, England), 2021 Jun 14
Seminars in radiation oncology, 2016-04
Advances in radiation oncology, 2017
Gynecologic oncology, 2019-03
The New England Journal of Medicine, 2024 Feb 29
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2024 Aug 24
Lancet (London, England), 2024 Oct 11